Journal: The Journal of Heart and Lung Transplantation

Abbreviation

J Heart Lung Transplant

Publisher

Elsevier

Journal Volumes

ISSN

1053-2498
1557-3117

Description

Filters

2011 - 201952020 - 20258
Reset filters

Search Results

Publications 1 - 10 of 13
  • The Depolarization Amplitude of the Electromyogram is a Measure of End-Diastolic Ventricular Volume
    Item type: Other Journal Item
    Dual, Seraina A.; Hall, S.; Sauer, Mareike; et al. (2020)
    The Journal of Heart and Lung Transplantation
  • Deactivation of LVAD support for myocardial recovery—surgical perspectives
    Item type: Review Article
    Nickel, Ian; Potapov, Evgenij; Sun, Benjamin; et al. (2024)
    The Journal of Heart and Lung Transplantation
    Left ventricular assist devices (LVADs) are excellent therapies for advanced heart failure patients either bridged to transplant or for lifetime use. LVADs also allow for reverse remodeling of the failing heart that is often associated with functional improvement. Indeed, growing enthusiasm exists to better understand this population of patients, whereby the LVAD is used as an adjunct to mediate myocardial recovery. When patients achieve benchmarks suggesting that they no longer need LVAD support, questions related to the discontinuation of LVAD therapy become front and center. The purpose of this review is to provide a surgical perspective on the practical and technical issues surrounding LVAD deactivation.
  • Avoidance of Outflow Graft Extrinsic Compression in Polytetrafluoroethylene Reinforcements of the Bend Relief Component
    Item type: Other Journal Item
    Potapov, Evgenij V.; Kaufmann, Friedrich; Mueller, Marcus; et al. (2019)
    The Journal of Heart and Lung Transplantation
  • Bacteriophage therapy as a treatment option for complex cardiovascular implant infection: The German Heart Center Berlin experience
    Item type: Journal Article
    Tkhilaishvili, Tamta; Potapov, Evgenij; Starck, Christoph; et al. (2022)
    The Journal of Heart and Lung Transplantation
    Conventional antimicrobials have low or no activity against multidrug-resistant or chronic implant-associated infections. Lytic bacteriophages can rapidly and selectively kill bacteria, and can be combined with antibiotics. However, clinical experience of bacteriophage therapy in patients with cardiovascular infections is limited. We documented the outcome and safety of intravenous and local adjunctive bacteriophage therapy, to treat chronic relapsing cardiovascular implant infections at our institution.
  • The Effect of Preload Change on QRS Amplitude in Advanced Heart Failure Patients
    Item type: Other Journal Item
    Pergantis, Panagiotis; Dual, Seraina A.; Schmid Daners, Marianne; et al. (2019)
    The Journal of Heart and Lung Transplantation
  • Expression of extra domain A containing fibronectin in chronic cardiac allograft rejection
    Item type: Journal Article
    Franz, Marcus; Berndt, Alexander; Gruen, Katja; et al. (2011)
    The Journal of Heart and Lung Transplantation
  • Impact of complications on survival outcomes in different temporary mechanical circulatory support techniques: A large retrospective cohort study of cardiac surgical and nonsurgical patients
    Item type: Journal Article
    Ott, Sascha; Germinario, Lorenzo; Müller-Wirtz, Lukas M.; et al. (2025)
    The Journal of Heart and Lung Transplantation
    Background: Temporary mechanical circulatory support (tMCS) has become a standard treatment in cardiogenic shock but is associated with high complication rates. This study analyzes common complications associated with modern tMCS devices and their impact on mortality depending on the tMCS approach. Methods: We conducted a retrospective single-center analysis of patients with all-cause cardiogenic shock treated with veno-arterial extracorporeal life support, microaxial flow pump, and a combination of both (ECMELLA). The primary outcome was the impact of cumulative complications on mortality, evaluated separately for nonsurgical (non-PCCS) and cardiac surgical (PCCS) patients. Secondary outcomes included the impact of complications on mortality stratified by tMCS type and rates of bleeding, the need for renal replacement therapy (RRT), hemolysis, neurological complications, bloodstream infections, and ischemic limb complications. Results: We included 493 patients, totaling 4,881 days on tMCS support. Non-PCCS patients with 1 complication had a hazard ratio (HR) of 1.92 (95% confidence interval [CI]: 1.22, 3.00, p = 0.004) for mortality and 3.73 (95% CI: 2.48, 5.60, p < 0.001) for 2 or more complications compared to those without complications. In PCCS patients, 1 complication was associated with an HR of 2.22 (95% CI: 1.29, 3.81, p = 0.004) and 3.44 (95% CI: 2.04, 5.78, p < 0.001) for 2 or more complications. The most common complications in both non-PCCS and PCCS patients were bleeding (33% and 60%), need for RRT (31% and 43%), and severe hemolysis (26% and 35%). Conclusion: Complications among tMCS-treated patients are common and clearly associated with an elevated mortality risk.
  • Complications related to the access site after transaxillary implantation of a microaxial left ventricular assist device
    Item type: Journal Article
    Lewin, Daniel; Nersesian, Gaik; Lanmüller, Pia; et al. (2023)
    The Journal of Heart and Lung Transplantation
    Background: Impella 5.0 and 5.5 (summarized as Impella 5+) are microaxial, catheter-based left ventricular assist devices (LVAD) that are implanted via a vascular graft sutured to the axillary artery and provide blood flow of up to 5.5 liter/min. This study aims to investigate the incidence of long-term complications following circulatory support with Impella 5+. Methods: A single-center retrospective analysis of 203 consecutive adult patients treated between January 2017 and September 2021 with a surgically implanted Impella 5.0 or 5.5 via a vascular graft sutured to the axillary artery. Results: The median Impella support duration was 8 days. Of 203 patients, 78 (38.4%) died while on temporary mechanical circulatory support. Fifty-five (27.1%) were successfully weaned from Impella 5+ and 70 (34.5%) were bridged to a durable LVAD with a median follow-up time of 232 (IQR 68.5, 597) days after Impella 5+ explantation. In 119 of these patients, the Impella was explanted and the vascular graft was shortened, ligated, and pushed under the pectoralis muscle; in 6 patients early graft infection prompted complete graft removal during explantation. In addition, 13 patients (10.9%) developed a late-onset graft infection after a median of 86 days, requiring complete (n = 10) or partial (n = 2) explantation of the retained graft. In 1 patient, the graft infection was successfully treated by conservative therapy. Our analysis identified no specific risk factors for graft infections. Of the 203 patients, 5 (2.5%) developed a brachial plexus injury resulting in neurological dysfunction. Conclusions: In 10.9% of patients, retaining the vascular graft was complicated by a late graft infection. Complete explantation of the graft prosthesis may decrease the infection rate, but may in turn increase the risk of brachial plexus injury. On the other hand, this method offers the possibility of bedside explantation.
  • Selective imaging of chronic cardiac rejection using a human antibody specific to the alternatively spliced EDA domain of fibronectin
    Item type: Journal Article
    Franz, Marcus; Hilger, Ingrid; Grün, Katja; et al. (2013)
    The Journal of Heart and Lung Transplantation
  • Results of non-elective withdrawal of continuous-flow left ventricular assist devices in selected patients
    Item type: Journal Article
    Knierim, Jan; Tsyganenko, Dmytro; Stein, Julia; et al. (2023)
    The Journal of Heart and Lung Transplantation
    Background: Protocols have been developed to identify patients for elective withdrawal of continuous-flow left ventricular device (cfLVAD) support. However, little is known about non-elective explantation or decommissioning of cfLVADs. Methods: A retrospective analysis of all patients who underwent left ventricular assist device (LVAD) explantation or decommissioning at a single center between 2002 and 2021 was performed. Results: Sixty-one patients underwent withdrawal of a cfLVAD (HeartMate II [Abbott] n = 17, HeartMate 3 [Abbott] n = 2, HeartWare HVAD [Medtronic] n = 36, INCOR [Berlin Heart] n = 6). The median follow-up after withdrawal was 1,039 days. The survival at 5 years was 76.1% (95% CI: 64.2%-95.2%). Predictors of worse outcomes in univariate regressive analysis were the duration of heart failure and the age at LVAD implantation. Of the 61 patients, 40 underwent elective withdrawal following a specific protocol. The other twenty-one patients underwent non-elective withdrawal of the cfLVAD because of device infection (n = 12), device thrombosis (n = 6), device malfunction (n = 2) or due to acute intracerebral bleeding (n = 1), also with an excellent survival at 5 years of 81.3%. (95% CI: 63.8-1). The withdrawal was performed in these patients even though they did not fulfill established criteria for successful explantation or decommissioning like clinical stability (n = 21), left ventricular end-diastolic diameter ≤ 55 mm (n = 3), performance of right heart catheterization (n = 6), or pulmonary artery wedge pressure ≤ 15 mm Hg (n = 3). Conclusion: Non-elective withdrawal is possible in selected patients after discussion in a team of experienced cardiac surgeons, cardiologists, technicians, and VAD coordinators. The appropriate preoperative assessment before decommissioning or explantation of a cfLVAD warrants further investigation.
Publications 1 - 10 of 13